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Abstract: The optimal blood pressure (BP) guidelines in Asian populations have not been determined.
We compared all-cause and cardiovascular mortality based on the Joint National Committee 7 (JNC7)
and 2017 American College of Cardiology/American Heart Association (ACC/AHA) guidelines.
The National Health Insurance System-National Health Screening Cohort (NHIS-HEALS) and Korea
National Health and Nutrition Examination Survey (KNHANES) were utilized. BPs were classified
into three groups according to each guideline, and survival rates were analyzed with Kaplan-Meier
curves and log-rank tests. Hazard ratios (HRs) were calculated using multivariable cox regression
analyses, and the discriminatory ability for clinical outcomes was assessed by Harrell’s C-indexes.
The JNC7 guidelines demonstrated a linear association between BP levels and survival outcomes.
Adjusted HRs from the JNC7 guidelines differentiated the hypertension group (≥140/90) from the
pre (130/80–139/89) and normal (<130 and <80) BP groups in clinical outcomes. In contrast, the 2017
ACC/AHA guidelines showed inconsistent survival outcomes according to BP classification (normal:
<120 and <80, elevated: 120–129, and <80, and HTN: ≥130/80). According to Harrell’s C-indexes,
the JNC7 guidelines had greater discrimination ability in survival outcomes in the NHIS-HEALS
dataset. Our results suggest that the JNC7 guidelines are more appropriate than the 2017 ACC/AHA
guidelines in Korean populations.
Keywords: hypertension; mortality; guidelines; blood pressure
1. Introduction
In 2017, the American College of Cardiology/American Heart Association (ACC/AHA) published
new blood pressure (BP) management guidelines that included changing the diagnostic standard
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for hypertension from a starting BP of 140/90 mm Hg, as in the Joint National Committee 7 (JNC7)
guidelines, to a BP of 130/80 mm Hg. Additionally, the 2017 ACC/AHA guidelines recommend
antihypertensive medication for adults at high risk of cardiovascular disease (CVD) with systolic BP
(SBP) 130 to 139 mm Hg or diastolic BP (DBP) 80 to 89 mm Hg as well as treatment to lower SBP/DBP
to <130/80 mm Hg for all adults taking antihypertensive medication [1].
The systolic blood pressure intervention trial (SPRINT) and recent meta-analysis revealed an
intensive BP reduction with antihypertensive treatment was beneficial in reducing cardiovascular
outcomes according to the new ACC/AHA guidelines [2,3]. Subsequent studies supported the
appropriateness of the new guidelines and have shown a linear association between BP levels, all-cause
mortality, and the risk of CVD with the lowest risk at a SBP level less than 130 mm Hg [4,5].
In contrast, several studies, including the valsartan in elderly isolated systolic hypertension
(VALISH) and action to control cardiovascular risk in diabetes (ACCORD) studies, failed to demonstrate
the benefit of the new BP guidelines [6,7] and inconsistent findings make it difficult to broadly apply the
2017 ACC/AHA guidelines. Indeed, the 2018 European guidelines for the management of hypertension
maintained the existing hypertension definition of 140/90 mm Hg [8].
Guidelines for hypertension need to consider the disparity of country- or race-specific risk factors.
BP related CVDs are more common in Asians than in Westerners [9]. However, it remains unknown
whether intensive BP reduction leads to improved all-cause mortality and cardiovascular outcomes.
Moreover, the optimal guidelines for discriminating high risk groups in terms of hypertension in Asian
populations have not been determined.
Therefore, we aimed to compare all-cause and CVD mortality in a Korean population according
to the JNC7 and 2017 ACC/AHA guidelines using two large nationally representative databases.
2. Materials and Methods
2.1. Study Population and Data Collection
2.1.1. National Health Insurance System-National Health Screening Cohort (2006–2015 NHIS-HEALS)
This study was based on data obtained from the NHIS-HEALS, a nationally retrospective cohort
study conducted by the Korea Centers for Disease Control and Prevention. The NHIS is a universal
health coverage program, and all insured individuals and their dependents are required to undergo
general health examinations every 2 years. The National Health Examination followed standardized
procedures, and its validity is described elsewhere [10].
Study populations were followed from 1 January 2006 until the date of a cardiovascular event,
death, or 31 December 2015, whichever came first. We extracted 1,021,208 participants aged 30–74 years
whose data were available and excluded individuals who met any of the following criteria (n = 878,590):
Younger than 30 or older than 75 years of a age; history of hospitalization for a diagnosis of myocardial
infarction (MI; Korean Standard Classification of Diseases, KCD codes I21–I23) or stroke (KCD codes
I60–I64); any type of malignant cancer; death in the year of enrolment; single medical record after 2006;
and those with missing SBP, DBP, or death data. Following these exclusions 142,618 participants were
included in the final analysis as shown in Figure 1.
Int. J. Environ. Res. Public Health 2019, 16, 5134 3 of 13
Int. J. Environ. Res. Public Health 2019, 16, x 3 of 14 
 
 
Figure 1. Flow chart of the study population. 
Self-reported cigarette smoking and alcohol consumption were determined by questionnaire. 
Each participant was categorized as a non-smoker, ex-smoker, or current smoker with respect to 
smoking status. Participants were categorized as non-drinkers, intermittent drinkers (≤3–4 times a 
week), or daily drinkers with respect to alcohol use. Physical activity was divided into five groups 
according to the amount of exercise per week, and household income was divided into five groups 
based on the 10th quantile information. 
BP was measured at local hospitals, each of which met the internal and external quality control 
procedures of the Korean Association of External Quality Assessment Service. After participants 
rested while seated for at least 2 min, and BP measurements were taken by digital or automatic 
monitors during the health examination. All BP measurements, including BP data before the index 
period, were used to calculate mean BP. 
2.1.2. Korea National Health and Nutrition Examination Survey (2007–2015 KNHANES Cohort) 
We obtained data from the 2007–2015 Korean National Health and Nutrition Examination 
Survey (KNHANES) cohort, a nationally representative survey conducted by the Korean Ministry of 
Health and Welfare. KNHANES datasets have been provided publicly, 10 but recent datasets have 
been further matched with death information from any cause. As a result, the data can be used for 
nationally representative death statistics. Study populations were followed from 1 January 2007 to 31 
December 2015. 
We extracted 73,353 participants aged 30–74 years and excluded participants who met any of the 
following criteria (n = 35,518): Participants younger than 30 or older than 75 years, a history of stroke, acute 
MI, or any type of malignant cancer, death in the year of enrollment, and those with missing SBP, DBP, or 
death data. Following these exclusions 37,835 participants were included in the final analysis as shown in 
Figure 1. 
Self-reported cigarette smoking and alcohol consumption were determined by questionnaire. Each 
participant was categorized as a non-smoker, ex-smoker, or current smoker with respect to smoking 
status. Participants were also asked about the frequency of their alcohol intake and weekly physical 
activity. Alcohol use was defined if one of two criteria was satisfied: Drinking quantity (≥7 drinks for 
males and ≥5 drinks for females) and frequency (≥2 times per week). 
BP measurements were taken at local examination centers by trained examiners. BP was measured 
three times, and the average of the second and third measurements was used for analysis [10]. 
2.2. Outcome Measurement 
The primary outcomes of the study were all-cause mortality and all cardiovascular mortality. All 
cardiovascular mortality was defined as death from a disease of the circulatory system (KCD codes I00–
I99). We selected myocardial infarction (MI, KCD codes I21–I23), hemorrhagic stroke (KCD codes I60–
Figure 1. Flow chart of the study population. A: 2006–2015 NHIS-HEALS; B: 2007–2015 KNAHES.
Self-reported cigarette smoking and alcohol consumption were determined by questionnaire.
Each participant was categorized as a non-smoker, ex-smoker, or current smoker with respect to
smoking status. Participants were categorized as non-drinkers, intermittent drinkers (≤3–4 times
a week), or daily drinkers with respect to alcohol use. Physical activity was divided into five groups
according to the amount of exercise per week, and household income was divided into five groups
based on the 10th quantile information.
BP was measured at local hospitals, each of which met the internal and external quality control
procedures of the Korean Association of External Quality Assessment Service. After participants rested
while seated for at least 2 min, and BP measurements were taken by digital or automatic monitors
during the health examination. All BP measurements, including BP data before the index period,
were used to calculate mean BP.
2.1.2. Kor a National Health and Nutrition Examination Survey (2007–2015 KNHANES Cohort)
We obtained data from the 2007–2015 Korean National Health and Nutrition Examination Survey
(KNHANES) cohort, a nationally representative survey conducted by the Korean Ministry of Health
and elfare. KNHANES datasets have been provided publicly, 10 but recent datasets have been
further matched with death information from any cause. As a result, the data can be used for
nationally representative death statistics. Study populations were followed from 1 January 2007 to
31 December 2015.
We extracted 73,353 participants aged 30–74 years and excluded participants who met any of the
following criteria (n = 35,518): Participants younger than 30 or older than 75 years, a history of stroke,
acute MI, or any type of malignant cancer, death in the year of enrollment, and those with missing SBP,
DBP, or death data. Following these exclusions 37,835 participants were included in the final analysis
as shown in Figure 1.
Self-reported cigarette smoking and alcohol consumption were determined by questionnaire. Each
participant was categorized as a non-smoker, ex-smoker, or current smoker with respect to smoking
status. Participants were also asked about the frequency of their alcohol intake and weekly physical
activity. Alcohol use was defined if one of two criteria was satisfied: Drinking quantity (≥7 drinks for
males and ≥5 drinks for females) and frequency (≥2 times per week).
BP measurements were taken at local examination centers by trained examiners. BP was measured
three times, and the average of the second and third measurements was used for analysis [10].
2.2. Outcome Measurement
The primary outcomes of the study were all-cause mortality and all cardiovascular mortality.
All cardiovascular mortality was defined as death from a disease of the circulatory system (KCD
codes I00–I99). We selected myocardial infarction (MI, KCD codes I21–I23), hemorrhagic stroke
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(KCD codes I60–I62), and ischemic stroke (KCD code I63) for inclusion among the detailed causes of
cardiovascular mortality.
2.3. Statistical Analysis
BPs were classified into three groups according to each guideline. Under the JNC7 guidelines,
BPs were categorized as follows: normal (<130 and <80), pre-hypertension (130/80–139/89),
and hypertension (HTN, ≥140/90). Under the 2017 ACC/AHA guidelines, BPs were classified
as normal (<120 and <80), elevated (120–129 and <80), and HTN (≥130/80). The characteristics of
the study population were presented as means ± standard deviations and frequencies (percentages).
Groups were compared using one-way analysis of variance (ANOVA) for continuous variables and
chi-square tests for categorical variables.
The survival rates of each group according to the adjustment criteria presented in each guideline
were analyzed by Kaplan-Meier curves and log-rank tests. The warranty period was defined as the
time required for the cumulative mortality incidence to reach 0.5% for each group. If the 0.5% threshold
was not met, the value was expressed as the time of the last follow-up. In addition, incidence per 1000
person-years was calculated for each group. The hazard ratios (HRs), 95% confidence intervals (CIs),
and p values for trends with reference to the pre-HTN group (130/80–139/89) in the JNC7 guidelines
and the elevated BP group (120–129 and <80) in the 2017 ACC/AHA guidelines were calculated using
multivariable Cox regression analyses after adjusting for age, sex, and body mass index (BMI) in the
KNHANES cohort and age, sex, BMI, physical activity, household income, smoking status, alcohol
status, fasting serum glucose, and total cholesterol in the NHIS-HEALS cohort. The KNAHES cohort
had a smaller number of events compared to the NHIS-HEALS cohort. Therefore, we adjusted the
KNAHES cohort for the smallest exploratory variable, while the NHIS-HEALS cohort was adjusted
for additional variables. To evaluate the predictability of the JNC7 and 2017 ACC/AHA guidelines,
we calculated Harrell’s c-index (95% CI). To calculate the 95% CIs and p-values for Harrell’s C-index and
the differences between JNC7 and ACC/AHA, we used a bootstrap method and resampled 1000 times.
The study was approved by the Institutional Review Board of Yonsei University Health System (IRB
number: 3-2018-0160), and the requirement for informed consent was waived. All statistical analyses
were performed using SAS software, version 9.4 (SAS Institute Inc., Cary, NC, USA). All statistical tests
were two-sided, and statistical significance was determined at p < 0.05.
3. Results
Using the NHIS-HEALS and KNAHES datasets of 1,021,208 and 73,353 individuals, respectively,
we identified 142,618 and 37,835 adults for inclusion in this study. The number of all-cause mortality
(ACM), all cardiovascular deaths (ACD), and major cardiovascular deaths (MACE; acute MI, ischemic
stroke, and hemorrhagic stroke) in each dataset are shown in Figure 1. During follow-up, 4611 ACM
and 819 CVD events occurred in the NHIS-HEALS cohort, and 789 ACM and 155 CVD events occurred
in the KNAHES cohort. Table 1 presents the baseline characteristics according to BP levels under the
two different criteria. The prevalence of hypertension was estimated to be 40.64% (NHIS-HEALS) and
44.8% (KNAHES) based on the 2017 ACC/AHA guidelines, which was a dramatic increase compared
to the 9.64% (NHIS-HEALS) and 18.4% (KNAHES) prevalence rates based on the JNC7 guidelines.
Individuals with a higher BP tended to be older, consumed more alcohol, had a higher BMI, and had
higher fasting serum glucose levels in both cohorts.
Figure 2 shows the cumulative incidence of the three outcomes (ACM, ACD, and MACE) for
each guideline using Kaplan-Meier curves and log-rank tests. Based on the JNC7 guidelines, there
was a significant linear trend towards an increased risk of all three outcomes with worse BP control
regardless of dataset. The 2017 ACC/AHA guidelines, however, showed different results. In the
NHIS-HEALS dataset, the 2017 ACC/AHA guidelines showed increased incidence of all three outcomes
in sequential BP groups, but in the KNAHES dataset, the cumulative incidence of ACM, ACD,
and MACE was highest in the elevated BP group, followed by the HTN and normal BP groups.
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Table 1. Baseline characteristics according to JNC7 and 2017 ACC/AHA guidelines.
Guidelines JNC7 Guidelines 2017 ACC/AHA Guidelines
2006–2015 NHIS-HEALS <130 and <80(n = 84,653)
130/80–139/89
(n = 44,214)
≥140/90
(n = 13,751) p-Value
1 <120 and <80
(n = 53,374)
120–129 and
<80 (n = 31,279)
≥130/80
(n = 57,965) p-Value
1
Age 45.53 ± 10.52 49.36 ± 11.26 53.92 ± 11.94 <0.0001 44.04 ± 9.7 48.09 ± 11.35 50.45 ± 11.58 <0.0001
Female Sex, N (%) 38948 (46.01) 14,321 (32.39) 5023 (36.53) <0.0001 27,377 (51.29) 11571 (36.99) 19344 (33.37) <0.0001
Height, m2 163.76 ± 8.81 164.63 ± 9.15 162.85 ± 9.38 <0.0001 163.42 ± 8.59 164.35 ± 9.15 164.21 ± 9.24 <0.0001
Weight, kg 62.46 ± 10.46 67.11 ± 11.21 67.14 ± 11.94 <0.0001 60.87 ± 10.04 65.17 ± 10.59 67.11 ± 11.39 <0.0001
BMI, kg/m2 23.21 ± 2.84 24.67 ± 2.98 25.21 ± 3.24 <0.0001 22.71 ± 2.74 24.05 ± 2.81 24.8 ± 3.05 <0.0001
Physical activity, N (%) <0.0001 <0.0001
0 43,192 (52.57) 20,980 (48.83) 6884 (51.54) 28,066 (54.2) 15126 (49.79) 27,864 (49.47)
1–2 23,590 (28.71) 13,070 (30.42) 3533 (26.45) 14,606 (28.21) 8984 (29.57) 16,603 (29.48)
3–4 9530 (11.6) 5235 (12.18) 1504 (11.26) 5856 (11.31) 3674 (12.09) 6739 (11.97)
5–6 2141(2.61) 1150 (2.68) 380 (2.85) 1254 (2.42) 887 (2.92) 1530 (2.72)
Almost everyday 3708(4.51) 2531 (5.89) 1055 (7.9) 2001 (3.86) 1707 (5.62) 3586 (6.37)
Household income, N (%) <0.0001 <0.0001
1–2 11,982 (14.41) 6366 (14.66) 2279 (16.74) 7450 (14.18) 4532 (14.79) 8645 (15.16)
3–4 11,231 (13.5) 5834 (13.44) 2056 (15.1) 7084 (13.49) 4147 (13.53) 7890 (13.84)
5–6 13,664 (16.43) 7278 (16.77) 2438 (17.91) 8407 (16.01) 5257 (17.16) 9716 (17.04)
7–8 22,734 (27.34) 11,374 (26.2) 3340 (24.53) 14,441 (27.49) 8293 (27.07) 14,714 (25.8)
9–10 23,555 (28.32) 12,559 (28.93) 3503 (25.73) 15,143 (28.83) 8412 (27.45) 16,062 (28.17)
Smokers, N (%) 27,345 (33.27) 17,041 (39.69) 4827 (36.24) <0.0001 15,827 (30.55) 11518 (37.92) 21868(38.87) <0.0001
Alcohol drinkers, N (%)
Non-drinker 45,514 (54.86) 20,411 (47.07) 6732 (50.1) 29,806 (57.03) 15708 (51.17) 27,143 (47.79)
Intermittent drinker 35,851 (43.22) 21,417 (49.39) 6007 (44.71) 21,708 (41.54) 14143 (46.07) 27,424 (48.28)
Daily drinker 1593 (1.92) 1535 (3.54) 697 (5.19) 747 (1.43) 846 (2.76) 2232 (3.93)
SBP, mm Hg 116.16 ± 11.73 130.75 ± 12.3 146.66 ± 16.25 <0.0001 111.83 ± 10.23 123.55 ± 10.36 134.52 ± 14.96 <0.0001
DBP, mm Hg 72.67 ± 8.2 82.72 ± 8.34 90.37 ± 11.06 <0.0001 70.64 ± 7.87 76.13 ± 7.55 84.53 ± 9.63 <0.0001
Fasting Glucose, mg/dL 93.47 ± 22.22 98.08 ± 25.49 103.91 ± 32.39 <0.0001 91.79 ± 20.37 96.33 ± 24.8 99.46 ± 27.4 <0.0001
Total cholesterol, mg/dL 192.03 ± 35.65 200.21 ± 36.33 204.12 ± 38.42 <0.0001 189.15 ± 34.95 196.95 ± 36.3 201.14 ± 36.87 <0.0001
AST, mg/dL 24.6 ± 17.94 27.32 ± 23.45 29.21 ± 22.55 <0.0001 23.7 ± 14.59 26.14 ± 22.45 27.77 ± 23.26 <0.0001
ALT, mg/dL 24.12 ± 22.32 29 ± 28.98 30.15 ± 26.87 <0.0001 22.58 ± 20.05 26.75 ± 25.53 29.27 ± 28.5 <0.0001
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Table 1. Cont.
Guidelines JNC7 Guidelines 2017 ACC/AHA Guidelines
2007–2015 KNAHES
Cohort
<130 and <80
(n = 20,903)
130/80–139/89
(n = 9983)
≥140/90
(n = 6949) p-value
1 <120 and <80
(n = 17,989)
120–129 and
<80 (n = 2914)
≥130/80
(n = 16,932) p-value
1
Age 48.4 ± 12.5 52.0 ± 11.9 55.4 ± 11.6 <0.0001 46.765 ± 11.9 58.469 ± 11.709 53.439 ± 11.933 <0.0001
Female Sex, N (%) 13704 (65.56) 4714 (47.22) 3175 (45.69) <0.0001 11,986 (66.63) 1718 (58.96) 7889 (46.59) <0.0001
BMI, kg/m2 23.2 ± 3.1 24.5 ± 3.3 25.1 ± 3.3 <0.0001 5623 (32.20) 1039 (36.96) 7504 (45.87) <0.0001
Physical activity, N (%) 1233 (6.15) 603 (6.31) 430 (6.46) 00.6341 2266 (6.25) 1080 (6.25) 153 (5.52) 0.2307
Household income, N (%) <0.0001 <0.0001
Q1 2988 (14.49) 1654 (16.83) 1616 (23.63) 2199 (12.39) 789 (27.51) 3270 (19.62)
Q2 5277 (25.60) 2518 (25.63) 1829 (26.74) 4464(25.15) 813 (28.35) 4347 (26.08)
Q3 6128 (29.72) 2735 (27.83) 1764 (25.79) 5415 (30.51) 713 (24.86) 4499 (27.00)
Q4 6224 (30.19) 2919 (29.71) 1630 (23.83) 5671 (31.95) 553 (19.28) 4549 (27.30)
Smokers, N (%) 6662 (32.86) 4361 (45.19) 3143 (46.85) <0.0001 7573 (45.48) 978 (37.94) 7085 (48.50) <0.0001
Alcohol drinkers, N (%) 8551 (44.46) 4234 (48.50) 2851 (48.51) <0.0001 23.072 ± 3.072 24.238 ± 3.151 24.751 ± 3.295 <0.0001
SBP, mm Hg 108.22 ± 9.639 124.22 ± 8.702 143.71 ± 14.043 <0.0001 105.71 ± 7.833 123.71 ± 2.93 132.22 ± 14.75 <0.0001
DBP, mm Hg 69.876 ± 6.256 81.892 ± 4.81 90.245 ± 9.73 <0.0001 69.367 ± 6.233 73.017 ± 5.429 85.32 ± 8.329 <0.0001
Pulse rate 57.557 ± 12.041 57.992 ± 12.185 60.412 ± 16.426 0.0002 57.531 ± 11.812 57.659 ± 12.921 59.042 ± 14.225 0.0217
Fasting Glucose, mg/dL 96.55 ± 21.92 101.61 ± 24.799 104.42 ± 25.985 <0.0001 95.269 ± 20.484 104.52 ± 28.035 102.76 ± 25.328 <0.0001
HbA1c, mg/dL 5.827 ± 0.946 5.981 ± 1.005 6.12 ± 1.081 <0.0001 5.765 ± 0.897 6.17 ± 1.124 6.036 ± 1.038 <0.0001
Insulin, mg/dL 9.209 ± 6.171 10.146 ± 6.963 10.575 ± 7.307 <0.0001 9.03 ± 5.71 10.361 ± 8.48 10.328 ± 7.114 <0.0001
Total cholesterol, mg/dL 187.28 ± 34.381 195.58 ± 35.902 199.46 ± 38.069 <0.0001 186.61 ± 34.123 191.4 ± 35.675 197.17 ± 36.854 <0.0001
Triglycerides, mg/dL 120.61 ± 88.481 154.95 ± 124.52 174.44 ± 142.33 <0.0001 116.98 ± 86.061 143.13 ± 99.322 162.93 ± 132.45 <0.0001
HDL-cholesterol, mg/dL 50.173 ± 11.786 48.489 ± 11.6 48.216 ± 11.583 <0.0001 50.481 ± 11.828 48.248 ± 11.331 48.377 ± 11.594 <0.0001
LDL-cholesterol, mg/dL 113.09 ± 31.369 116.23 ± 34.847 116.34 ± 38.254 <0.0001 112.82 ± 30.927 114.73 ± 33.952 116.28 ± 36.283 <0.0001
AST, mg/dL 21.302 ± 11.932 24.121 ± 14.125 25.489 ± 14.695 <0.0001 20.962 ± 11.371 23.416 ± 14.781 24.681 ± 14.376 <0.0001
ALT, mg/dL 19.931 ± 18.982 24.604 ± 18.695 25.672 ± 17.601 <0.0001 19.613 ± 18.845 21.904 ± 19.698 25.042 ± 18.262 <0.0001
BUN, mg/dL 14.144 ± 4.162 14.783 ± 4.362 15.098 ± 4.576 <0.0001 13.953 ± 4.065 15.326 ± 4.545 14.912 ± 4.454 <0.0001
Creatinine, mg/dL 0.812 ± 0.228 0.865 ± 0.259 0.869 ± 0.283 <0.0001 0.808 ± 0.219 0.837 ± 0.276 0.867 ± 0.269 <0.0001
WBC, mg/dL 5.951 ± 1.693 6.263 ± 1.761 6.423 ± 1.781 <0.0001 5.915 ± 1.685 6.175 ± 1.73 6.328 ± 1.771 <0.0001
Data are expressed as the mean ± SD or frequency (percentage). 1 p-values were calculated using one-way ANOVA, Chi-square test, and post-hoc analysis. Abbreviations: JNC7, the Joint
National Committee 7; 2017 ACC/AHA, 2017 American College of Cardiology/American Heart Association; SBP, Systolic blood pressure; DBP, diastolic blood pressure; AST, Aspartate
transaminase; ALT, Alanine aminotransferase; BUN, Blood Urea Nitrogen; WBC, White blood cell.
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Figure 2. Kaplan-Meier curves with log-rank tests for the cumulative incidence of for all-cause
mortality, all cardiovascular death, and major cardiovascular death according to JNC7 and 2017
ACC/AHA guidelines.
The warranty periods were defined as the duration in years that the cumulative mortality rate
remained <0.5%. Based on the JNC7 guidelines, the HTN group had an unfavorable warranty period
in all three outcomes compared to the elevated BP and normal BP groups in the two datasets. However,
according to the 2017 ACC/AHA guidelines, results were inconsistent between the NHIS-HEALS and
KNAHES datasets. Although the warranty periods for ACM and ACD were shortest in the HTN
group in the NHIS-HEALS dataset, the elevated BP group had the shortest warranty period for ACM
and ACD in the KNAHES dataset. Based on the JNC7 guidelines, the event rates for ACM, ACD,
and MACE per 1000 person-years increased linearly with increasing BP in both datasets. However,
according to the 2017 ACC/AHA guidelines, the cumulative incidence of ACM, ACD, and MACE was
highest in the elevated BP group, followed by the HTN and normal BP groups in the KNAHES dataset.
In other words, the 2017 ACC/AHA guidelines did not show linearity in warranty periods and event
rates per 1000 person-years Table 2.
Table 3 shows adjusted HRs for ACM, ACD, and MACE according to each guideline after adjusting
for all variables. Based on the JNC7 guidelines, the hazard ratio (95% CIs) was statistic lly significantly
higher in the HTN group in all three outcomes compared to the oth r two gr ups in both datasets:
ACM 1.84 (1.67–2.00), ACD 2. 2 (2.26–3.27), and MACE 3.25 (2.51–4.21) in the NHIS-HEALS dataset
and ACM 1.24 (1.05–1.48), ACD 1.83 (1.26–2.65), and MACE 1.73 (1.04–2.90) in the KNAHES dataset.
Unlike the JNC7 guidelines, t 2017 ACC/AHA guidelines showed different results between th two
datasets. The HTN group showed the highest hazard ratio in all three outcomes in the NHIS-HEALS
dataset: ACM 1.15 (1.06–1.24), ACD 1.76 (1.42–2.17), and MACE 2.09 (1.53–2.84). However, there were
no statistically significant differences between the normal group and the elevated BP group for ACD or
MACE in the NHIS-HEALS dataset. Conversely, in the KNAHES dataset, the hazard ratio for ACM was
significantly higher in the normal group than in the elevated BP group according to the 2017 ACC/AHA
guidelines. Moreover, based on the 2017 ACC/AHA guidelines, there was no statistically significant
difference for all three HRs between the elevated BP group and the HTN group in the KNAHES dataset.
Instead, the normal group had the lowest HRs for all three outcomes in the KNAHES dataset.
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Table 2. Warranty periods for all-cause mortality, all cardiovascular death, and major cardiovascular death according to JNC7 and 2017 ACC/AHA guidelines.
Guidelines 2006–2015 NHIS-HEALS 2007–2015 KNAHES Cohorts
Groups WarrantyPeriod (0.5%) n
Person-Time
(Years)
Events, N
(%)
Incidence per
1000 Person-Years
(95% CI)
Warranty
Period (0.5%) n
Person-Time
(Years)
Events, N
(%)
Incidence per
1000 Person-Years
(95% CI)
JNC7
ACM <130 and <80 3.59 84,653 784,456.07 1854 (2.19) 2.36 (0.15–4.57) 2.45 20,903 11,2374.2 352 (1.68) 3.13 (2.81–3.46)
130/80–139/89 2.42 44,214 407,805.67 1548 (3.50) 3.80 (0.73–6.86) 2.24 9983 54,240.97 220 (2.20) 4.06 (3.52–4.60)
≥140/90 1.24 13,751 123,886.58 1209 (8.79) 9.76 (4.22–15.30) 1.72 6949 38,376.21 226 (3.25) 5.89 (5.12–6.66)
ACD <130 and <80 9.67 84,653 784,456.07 254 (0.30) 0.32 (0.00–2.54) 8.19 20,903 11,2374.2 60 (0.29) 0.53 (0.40–0.67)
130/80–139/89 8.42 44,214 407,805.67 279 (0.63) 0.68 (0.00–3.75) 6.28 9983 54,240.97 38 (0.38) 0.70 (0.48–0.92)
≥140/90 2.75 13,751 123,886.58 286 (2.08) 2.31 (0.00–7.87) 3.5 6949 38,376.21 57 (0.82) 1.49 (1.10–1.87)
MACE <130 and <80 9.68 84,653 784,456.07 120 (0.14) 0.15 (0.00–2.37) 9.5 20,903 11,2374.2 32 (0.15) 0.29 (0.19–0.38)
130/80–139/89 9.84 44,214 407,805.67 136 (0.31) 0.33 (0.00–3.40) 9.5 9983 54,240.97 19 (0.19) 0.35 (0.19–0.51)
≥140/90 4.08 13,751 123,886.58 150 (1.09) 1.21 (0.00–6.78) 6.5 6949 38,376.21 29 (0.42) 0.76 (0.48–1.03)
2017
ACC/AHA
ACM <120 and <80 3.51 53,374 494,529.82 1051 (1.97) 2.13 (0.00–4.91) 2.74 17,989 97,368.52 259 (1.44) 2.66 (2.34–2.98)
120–129 and <80 3.67 31,279 289,926.25 803 (2.57) 2.77 (0.00–6.41) 1.72 2914 15,005.72 93 (3.19) 6.20 (4.94–7.45)
≥130/80 1.83 57,965 531,692.25 2757 (4.76) 5.19 (2.50–7.87) 1.92 16,932 92,617.18 446 (2.63) 4.82 (4.37–5.26)
ACD <120 and <80 9.51 53,374 494,529.82 123 (0.23) 0.25 (0.00–3.04) 8.21 17,989 97,368.52 35(0.19) 0.36 (0.24–0.48)
120–129 and <80 6.59 31,279 289,926.25 131 (0.42) 0.45 (0.00–4.09) 3.28 2914 15,005.72 25 (0.86) 1.67 (1.01–2.32)
≥130/80 6.17 57,965 531,692.25 565 (0.97) 1.06 (0.00–3.75) 4.78 16,932 92,617.18 95 (0.56) 1.03 (0.82–1.23)
MACE <120 and <80 8.76 53,374 494,529.82 57 (0.11) 0.12 (0.00–2.90) 9.5 17,989 97,368.52 18 (0.10) 0.19 (0.10–0.27)
120–129 and <80 9.68 31,279 289,926.25 63 (0.20) 0.22 (0.00–3.86) 4.91 2914 15,005.72 14 (0.48) 0.93 (0.44–1.42)
≥130/80 9.34 57,965 531,692.25 286 (0.49) 0.54 (0.00–3.23) 8.16 16,932 92,617.18 48 (0.28) 0.51 (0.37–0.67)
Abbreviations: JNC7, the Joint National Committee 7; 2017 ACC/AHA, 2017 American College of Cardiology/American Heart Association; ACM: All-cause mortality; ACD: All cardiovascular
death; MACE: Major cardiovascular death; CI: Confidence interval.
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Table 3. Hazard ratios for all-cause mortality, all cardiovascular death, and major cardiovascular death
according to JNC7 and 2017 ACC/AHA guidelines.
Guidelines 2006–2015 NHIS-HEALS
Groups Adjusted HR(95% CI) 1
p-Value
for Trend Pairwise Comparison p-Value
JNC7
ACM <130 and <80 1
<0.0001
ref
130/80–139/89 1.10 (1.02–1.18) 0.0102 ref
≥140/90 1.84 (1.70–2.00) <0.0001 <0.0001 ref
ACD <130 and <80 1
<0.0001
ref
130/80–139/89 1.36 (1.13–1.62) 0.0011 ref
≥140/90 2.72 (2.26–3.27) <0.0001 <0.0001 Ref
MACE <130 and <80 1
<0.0001
ref
130/80–139/89 1.40 (1.08–1.81) 0.012 ref
≥140/90 3.25 (2.51–4.21) <0.0001 <0.0001 Ref
2017
ACC/AHA
ACM <120 and <80 1
<0.0001
ref
120–129 and <80 0.77 (0.69–0.84) <0.0001 ref
≥130/80 1.15 (1.06–1.24) 0.0005 <0.0001 Ref
ACD <120 and <80 1
<0.0001
ref
120–129 and <80 0.99 (0.77–1.28) 0.9098 ref
≥130/80 1.76 (1.42–2.17) <0.0001 <0.0001 Ref
MACE <120 and <80 1
<0.0001
ref
120–129 and <80 1.14 (0.79–1.65) 0.4968 ref
≥130/80 2.09 (1.53–2.84) <0.0001 <0.0001 Ref
Guidelines 2007–2015 KNAHES Cohorts
Groups Adjusted HR(95% CI) 2
p for
Trend Pairwise Comparison p-Value
JNC7
ACM <130 and <80 1
0.0234
ref.
130/80–139/89 0.97 (0.82–1.15) 0.7352 ref.
≥140/90 1.24 (1.05–1.46) 0.0128 0.0095 ref.
ACD <130 and <80 1
0.0022
ref.
130/80–139/89 1.00 (0.66–1.51) 0.9963 ref.
≥140/90 1.83 (1.26–2.65) 0.0015 0.0041 ref.
MACE <130 and <80 1
0.0482
ref.
130/80–139/89 0.91 (0.51–1.62) 0.7520 ref.
≥140/90 1.73 (1.04–2.90) 0.0361 0.0298 ref.
2017
ACC/AHA
ACM <120 and <80 1
0.0592
ref.
120–129 and <80 1.37 (1.08–1.74) 0.0101 ref.
≥130/80 1.18(1.01–1.38) 0.0407 0.1913 ref.
ACD <120 and <80 1
0.0051
ref.
120–129 and <80 2.59 (1.54–4.36) 0.0003 ref.
≥130/80 1.86 (1.25–2.77) 0.0022 0.1446 ref.
MACE <120 and <80 1
0.0654
ref.
120–129 and <80 2.88 (1.42–5.87) 0.0034 ref.
≥130/80 1.81 (1.04–3.15) 0.0363 0.1271 ref.
1 Adjusted for age, sex, BMI, physical activity, household income, smoking status, alcohol status, fasting serum
glucose, and total cholesterol. 2 Adjusted for age, sex, BMI. ACM: All-cause mortality; ACD: All cardiovascular
death; MACE: Major cardiovascular death; HR: Hazard ratio; CI: Confidence interval.
To evaluate the potential discriminatory ability of the two guidelines for clinical outcomes,
Harrell’s C-indexes were calculated and are presented in Table 4. These results suggest that the JNC7
guidelines have a greater discrimination ability in the NHIS-HEALS dataset and show no significant
difference between the two guidelines in the KNAHES dataset.
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Table 4. Discrimination ability for all-cause mortality, all cardiovascular death, and major cardiovascular
death according to JNC7 and 2017 ACC/AHA guidelines.
2006–2015 NHIS-HEALS 2007–2015 KNAHES Cohort
JNC 7 2017 ACC/AHA p-Value JNC 7 2017 ACC/AHA p-Value
ACM 0.622 (0.613–0.63) 0.605 (0.597–0.612) <0.0001 0.566 (0.546–0.584) 0.57 (0.551–0.586) 0.4237
ACD 0.682 (0.666–0.704) 0.656 (0.643–0.673) <0.0001 0.607 (0.561–0.649) 0.613 (0.575–0.645) 0.5854
MACE 0.692 (0.667–0.716) 0.663 (0.644–0.686) <0.0001 0.582 (0.533–0.636) 0.596 (0.544–0.639) 0.3861
JNC7, the Joint National Committee 7; 2017 ACC/AHA, 2017 American College of Cardiology/American Heart
Association; ACM: All-cause mortality; ACD: All cardiovascular death; MACE: Major cardiovascular death. p-values
were calculated using Harrell’s c-index.
4. Discussion
Hypertension is a major risk factor for cardiovascular morbidity and mortality [11]. Due to the
association of hypertension and BP, optimal BP thresholds and treatment goals have long been a source
of debate. Although the recent 2017 ACC/AHA guidelines recommend treating patients to reduce
SBP/DBP to <130/80 mm Hg [1], it is still uncertain whether such aggressive BP control results in
improved clinical outcomes. Moreover, there is little direct evidence to guide the choice of target BP in
Asian populations.
To address these unanswered questions, we compared clinical outcomes using the JNC7 and 2017
ACC/AHA guidelines in two nationally representative Korean population datasets. Based on the JNC7
guidelines, there was a linear association between BP levels and survival outcomes in both datasets.
Similarly, the HTN group had unfavorable survival outcomes as reflected by warranty periods and
event rates per 1000 person-years, regardless of dataset. In addition, adjusted HRs calculated using the
JNC7 guidelines were able to differentiate the HTN group from the elevated and normal BP groups
in all clinical outcomes. In contrast, the 2017 ACC/AHA guidelines showed inconsistent survival
outcomes according to BP classification in the two datasets. Moreover, the JNC7 guidelines had more
discrimination ability for all survival outcomes than the 2017 ACC/AHA guidelines according to
Harrell’s c-indexes in the NHIS-HEALS dataset.
It is uncertain why our results differ from the SPRINT study and recent meta-analyses [12] with
emphasis on the strict BP lowering treatment. The differences may be explained in part by country-
or ethnicity-specific factors and differing health environments. For example, the cutoff value for
the definition of obesity is lower for Asian populations than for Western populations [13]. Asian
populations tend to have a high salt intake, salt sensitivity, masked HTN, and nocturnal HTN [13].
Also, exaggerated morning BP surges are more frequent in Asian populations compared with Western
populations [13]. Therefore, the influence of BP on health outcomes may differ among Asians and
Westerners [14]. Future studies are warranted to clarify the possible mechanisms underlying the
differences related to race and ethnicity.
Additionally, several studies in Western populations demonstrated inconsistencies with the
SPRINT study. The SHEP (Systolic Hypertension in the Elderly Program) trial postulated that less
intensive BP control may be more suitable for older patients, [15] and a pooled analysis of the
ONTARGET and TRANSCEND trials suggested that excessive reduction of BP (SBP <120 mm Hg)
increased mortality and cardiovascular events compared to SBP between 120 and 140 mm Hg [16].
Furthermore, the post hoc analysis of the SPRINT trial found that even those with a lower baseline
CVD risk of <18.2% experienced more harm than benefit following strict BP lowering treatment [17].
The strict BP thresholds of the new guidelines may be more appropriate for use in younger patients
and in patients with higher CVD risk than those of the JNC7 guidelines. This is supported by recent
epidemiologic data from the NHIS-HEALS cohort in young hypertensive patients as well as in patients
with atrial fibrillation and HTN. Among young Korean adults with hypertension defined by the 2017
ACC/AHA guidelines, the risk of subsequent cardiovascular disease events was elevated compared to
those with normal BP, [18] and BP between 120 and 129/<80 mm Hg was found to be the optimal BP
treatment target for patients with atrial fibrillation undergoing hypertension treatment [19]. Therefore,
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it is reasonable that the benefits of intensive BP reduction according to the new guidelines may
differ according to age and associated cardiovascular risks. In our study, we used two independent
nationwide cohort databases, which enables a high degree of generalization of our results. The JNC7
guidelines showed consistent results and a linear association between BP level and survival outcome;
however, the 2017 ACC/AHA guidelines failed to find a linear relationship between all-cause or
cardiovascular mortality and BP classifications in the two datasets.
This study has several limitations. First, although BP measurement equipment in all health
examination institutions received quality assessment according to the Basic Act on National Health
Examination, the lack of device uniformity and single visit measurements may have introduced
some variability into our results. Unfortunately, it was impossible to measure home BP monitoring
and ambulatory BP monitoring in routine evaluations. Second, because the current study was
observational, confounding factors could result in over- or under-estimation of the effect of BP on
clinical outcomes. Third, we did not account for antihypertensive medications that may affect the
all-cause or cardiovascular mortality and could not conclude whether those who took antihypertensive
medications following the JNC7 had a significantly lower mortality than those following the 2017
ACC/AHA guidelines. Also, we did not consider the mortality of heart failure that could create
structural modification of the left ventricle [20]. Fourth, there is a possibility of sampling bias as our
results were not weighted due to a lack of information on sampling weights in the data obtained
from the NHIS-HEALS and KNHANES. Finally, our study population was composed of only Korean
adults, so the results may not be generalizable to other races or ethnicities. Further investigations are
required to evaluate and select the optimal BP guidelines and to determine the applicability of a new
BP threshold with consideration given to the differences in healthcare environments.
Nevertheless, our results represent real word data and reflect practical clinical conditions. To our
knowledge, this is the first study to directly compare the two guidelines in terms of all-cause and
cardiovascular mortality.
5. Conclusions
Unlike the 2017 ACC/AHA guidelines, the JNC7 guidelines demonstrated a linear association
between BP levels and survival outcomes in two nationwide datasets as well as good discrimination
ability in all survival outcomes. Collectively, our results suggest that the JNC7 guidelines are more
appropriate than the 2017 ACC/AHA guidelines in Korean populations.
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